These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones]. Lotz N MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793 [No Abstract] [Full Text] [Related]
23. Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities. Tang H; Yan Y; Feng Z; de Jesus RK; Yang L; Levorse DA; Owens KA; Akiyama TE; Bergeron R; Castriota GA; Doebber TW; Ellsworth KP; Lassman ME; Li C; Wu MS; Zhang BB; Chapman KT; Mills SG; Berger JP; Pasternak A Bioorg Med Chem Lett; 2010 Oct; 20(20):6088-92. PubMed ID: 20832306 [TBL] [Abstract][Full Text] [Related]
24. The hypoglycemic effect of ciglitazone in obese, hyperglycemic animal models. Chang AY; Wyse BM Prog Clin Biol Res; 1988; 265():177-92. PubMed ID: 3043443 [No Abstract] [Full Text] [Related]
25. Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents. Clark DA; Goldstein SW; Volkmann RA; Eggler JF; Holland GF; Hulin B; Stevenson RW; Kreutter DK; Gibbs EM; Krupp MN J Med Chem; 1991 Jan; 34(1):319-25. PubMed ID: 1992133 [TBL] [Abstract][Full Text] [Related]